Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader
The articles shown below are all about the Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader, through these related articles, you can get relevant information, notes in use, or latest trends about the Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader. We hope these news will give you the help you need. And if these Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader articles can't solve your needs, you can contact us for relevant information.
Revenue hit $242 million, up 96.2% y-o-y.Net profit reached $92 million, up 56.67% y-o-y.R&D investment stood at $23 million, up 85.72% y-o-y. Vazyme recently released the 2022 semi-annual report, revealing the robust growth in the first half of the year. Vazyme has been stepping up R&D efforts over
Our vision is to lead in biotechnology by driving innovation relentlessly, pursuing the highest standards in quality of products and services, and creating value for our customers.
English
简体中文